Study to evaluate the safety and tolerability of camizestrant in combination with atirmociclib in women with advanced breast cancer

Trial Identifier: D853CC00001
Sponsor: AstraZeneca
Start Date: April 2026
Primary Completion Date: December 2027
Study Completion Date: December 2027
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
GB Cambridge, GB, CB2 0QQ
GB London, GB, EC1M6BQ
GB Manchester, GB, M20 4GJ
US, MO Saint Louis, MO, US, 63108
US, RI East Providence, RI, US, 02915
US, TN Nashville, TN, US, 37203